LAUSR

Long-term Immunogenicity of BNT162b2 Vaccine in Patients With Solid Tumors In a previous cohort study, administration of the BNT162b2 vaccine in patients with solid tumors demonstrated a favorable safety and efficacy profile following the second vaccination, although gradual immunogenicity was observed compared with the general population.1 We had previously demonstrated at 6 months postvaccination a steady decline in antibody titers and seropositivity rates among patients with solid tumors treated at a center in Haifa, Israel, that were comparable with the general population.2 Because of declined immunity, a booster dose had been recommended by medical authorities. Although humoral response was extensively studied in patients with cancer, to our knowledge, there are few data regarding cellular immunity and the association with vaccine efficacy. In this study, we prospectively explored cellular and humoral pathways at 6 months postvaccination in patients with cancer who were receiving active antineoplastic treatment, as well as a subset of patients following receipt of a booster dose.